JASPER THERAPEUTICS INC (JSPR) Stock Price, Forecast & Analysis
NASDAQ:JSPR • US4718712023
JSPR Key Statistics, Chart & Performance
The current stock price of JSPR is 1.37 USD. In the past month the price decreased by -12.74%. In the past year, price decreased by -76.9%.
JSPR Technical Analysis
JSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JSPR. While JSPR seems to be doing ok healthwise, there are quite some concerns on its profitability.
JSPR Financial Highlights
Over the last trailing twelve months JSPR reported a non-GAAP Earnings per Share(EPS) of -6.02. The EPS decreased by -27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.38% | ||
| ROE | -786.63% | ||
| Debt/Equity | 0 |
JSPR Forecast & Estimates
14 analysts have analysed JSPR and the average price target is 12.92 USD. This implies a price increase of 843.07% is expected in the next year compared to the current price of 1.37.
JSPR Ownership
JSPR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 397.325B | ||
| AMGN | AMGEN INC | 16.84 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.8 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.94 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.91 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.1 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JSPR
Company Profile
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Company Info
JASPER THERAPEUTICS INC
2200 Bridge Pkwy Suite #102
Redwood City CALIFORNIA US
CEO: Bala Venkataraman
Employees: 64
Phone: 16505491400
JASPER THERAPEUTICS INC / JSPR FAQ
What does JASPER THERAPEUTICS INC do?
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Can you provide the latest stock price for JASPER THERAPEUTICS INC?
The current stock price of JSPR is 1.37 USD. The price increased by 3.79% in the last trading session.
What is the dividend status of JASPER THERAPEUTICS INC?
JSPR does not pay a dividend.
What is the ChartMill technical and fundamental rating of JSPR stock?
JSPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of JSPR stock?
JASPER THERAPEUTICS INC (JSPR) operates in the Health Care sector and the Biotechnology industry.
What is the ownership structure of JASPER THERAPEUTICS INC (JSPR)?
You can find the ownership structure of JASPER THERAPEUTICS INC (JSPR) on the Ownership tab.
Can you provide the short interest for JSPR stock?
The outstanding short interest for JASPER THERAPEUTICS INC (JSPR) is 12.86% of its float.